Skip to main content
TransThera Sciences (Nanjing), Inc. logo

TransThera Sciences (Nanjing), Inc. — Investor Relations & Filings

Ticker · 2617 ISIN · CNE100006T02 HKEX Manufacturing
Open in API
Filings indexed 80 across all filing types
Latest filing 2026-03-03 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2617

About TransThera Sciences (Nanjing), Inc.

https://www.transthera.com

TransThera Sciences (Nanjing), Inc. is a clinical-stage, R&D-driven biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecule therapies. Established in 2014, the company employs a clinical demand-oriented approach to address diseases with significant unmet medical needs. TransThera's pipeline is dedicated to generating first-in-class, best-in-class, and highly differentiated treatments, primarily targeting therapeutic areas such as oncology, inflammatory diseases, and cardiovascular conditions.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026
Regulatory Filings Classification · 95% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and public float. As it is a recurring regulatory filing regarding share capital and listing compliance that does not fit into specific categories like 'Share Issue' (which implies a specific event) or 'Director's Dealing', it is best classified as a Regulatory Filing (RNS).
2026-03-03 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026
Share Issue/Capital Change Classification · 100% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Stock Exchange. It details movements in authorized and issued share capital, including increases in share counts. This type of filing is a standard regulatory requirement for companies listed on the HKEX to report changes in securities, which falls under the category of 'Share Issue/Capital Change'.
2026-02-04 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 100% confidence The document is a 'Next Day Disclosure Return' (Form FF305) filed with the Hong Kong Stock Exchange. It details a specific change in the company's issued share capital resulting from a share placement/subscription. According to the filing definitions, announcements regarding new share issues or capital changes fall under the 'Share Issue/Capital Change' (SHA) category.
2026-01-20 English
COMPLETION OF PLACING OF NEW H SHARES UNDER THE GENERAL MANDATE
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement regarding the 'Completion of Placing of New H Shares' by TransThera Sciences (Nanjing), Inc. It details the successful issuance of new shares, the use of proceeds, and the resulting change in the company's shareholding structure. This falls directly under the definition of a share issue or capital change announcement.
2026-01-20 English
PLACING OF NEW H SHARES UNDER GENERAL MANDATE
Capital/Financing Update Classification · 100% confidence The document is an official announcement from TransThera Sciences regarding the 'Placing of New H Shares under General Mandate'. It details the terms of the share placement, the number of shares, the placing price, the use of proceeds, and the regulatory compliance (CSRC filings, Stock Exchange listing). This falls squarely under the definition of a capital/financing update, as it describes a specific fundraising activity through the issuance of new equity.
2026-01-13 English
VOLUNTARY ANNOUNCEMENT PRESENTATION OF CLINICAL DATA ANALYSIS OF TINENGOTINIB MONOTHERAPY IN PATIENTS WITH ADVANCED CHOLANGIOCARCINOMA AT 2026 ASCO GI
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement issued by TransThera Sciences regarding a poster presentation of clinical trial data at the 2026 ASCO GI symposium. It provides details on the study title, presentation format, and clinical findings related to their drug candidate, tinengotinib. Since it is a voluntary disclosure of business/clinical progress and does not fit into specific categories like financial reports, dividends, or board changes, it is classified as a general regulatory announcement.
2026-01-12 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.